Bristol-Myers adds 3 directors in agreement with JANA Partners

United States of America based company, Bristol-Myers Squibb Company's (BMY)'s latest closing price distance was -9.58% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -0.60% and 7.71% compared with the 20 Day Moving Average. This Company belongs to Medical sector. Essex Financial Services Inc. now owns 72,302 shares of the biopharmaceutical company's stock worth $4,225,000 after buying an additional 19,529 shares during the last quarter. The mean revenue estimate for the current fiscal period ending March 2017 is $4.74B by 12 brokerage firms. The stock has relative volume of 0.78. Cowen and Company set a $85.00 target price on shares of Bristol-Myers Squibb Company and gave the stock a "buy" rating in a research note on Thursday, December 1st. The company has a consensus rating of "Hold" and an average price target of $63.12.

Bristol-Myers Squibb Company (NYSE:BMY) last announced results for quarter ended on 31 Dec 2016, disclosing EPS of $0.63 The reported earnings per share topped the analyst's consensus by $-0.04 with the percentage difference between estimated and actual earnings arriving at -6.00%. This is built on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

Bristol-Myers Squibb Company (NYSE:BMY) jumped 0.35 percent and ended the day at $54.78. All of these Earnings estimates are a consensus recommendation of 14 Analysts. Bristol-Myers Squibb Company's dividend payout ratio is presently 58.87%. Analysts are forecasting earnings of $0.73 on a per share basis this quarter. During the same quarter in the previous year, the firm posted $0.38 earnings per share. Hence, the surprise factor was 18.5 percent. Billionaire Carl Icahn has taken a stake in drug maker Bristol-Myers Squibb. According to these analysts, the Low Revenue Estimate for Bristol-Myers Squibb Company is 4.55 Billion and the High Revenue Estimate is 4.92 Billion.

Jana Partners, a NY based investing firm, started building a stake past year and now holds a value between $500 million to $1 billion, reported by The Wall Street Journal.

The company shows its Return on Assets (ROA) value of 0%.

More news: Lindsay Lohan Says Her Headscarf Got Her Profiled at the Airport

Bristol-Myers, a global leader in biopharmaceutical, hasn't been able to convince shareholders that its product can compete against rivals like Merck & Co MRK. Based on a recent bid, the stock is trading -3.24% away from it's 52- week high and 117.76% away from its 52 week low. The company earned $5.24 billion during the quarter, compared to analysts' expectations of $5.14 billion.

During last 3 month it remained at -2.22%.

Its weaker competitive position has been reflected in its shares, off almost 8 percent this year.

Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. Institutional investors and hedge funds own 69.67% of the company's stock.

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.

  • Rita Burton